[go: up one dir, main page]

WO2014150996A1 - Traitement contre le cancer - Google Patents

Traitement contre le cancer Download PDF

Info

Publication number
WO2014150996A1
WO2014150996A1 PCT/US2014/024729 US2014024729W WO2014150996A1 WO 2014150996 A1 WO2014150996 A1 WO 2014150996A1 US 2014024729 W US2014024729 W US 2014024729W WO 2014150996 A1 WO2014150996 A1 WO 2014150996A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
drug
inhibitors
agents
drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/024729
Other languages
English (en)
Inventor
Knox Van Dyke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CBA Pharma Inc
Original Assignee
CBA Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CBA Pharma Inc filed Critical CBA Pharma Inc
Publication of WO2014150996A1 publication Critical patent/WO2014150996A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • Hie am COBOIMTC adsxdslstratiori Is used broadly to reifet to ttte.use of all of hee dra s, duriog a gives cycle of tre meM of my; t & m. . T1 ⁇ 4 various agent might be idmb sered serially or sim ltane usy.
  • tfecy ®rv all administered suc that ooe m mom of the drags remains bo the pabcsfs system -wfei each additional drug is adroir sewd.
  • Avosik (Bovaek mah) -Vascular etKiolhelial rowh factor Inhibitor (VEGF);
  • SOSJ Hixkme degeeyhi.se (HDAC) inhbit r are a cl ss of a nts that mixiu e gene cxpr 3 ⁇ 4;-.- s; by ioereasiag .histone acety!atiarL Hisioae acetyl&tioo stooo ie* the expression of h ior pprsssiori factors by some rum r sappesarori genes, Bcc ase these age a able to r gulate the c nro of specific geocs, mc!odm loaior sup ess r genes, the are viable candidates for uso 1 ⁇ 2 coo ear ireatmersL
  • Valproic acid a owerful HDAC inhibitor, relieves re resson of traoacriprioo f cos, causng hyperaeetyaticfo of h nes hrtdhiiing tumor growth and .metast sis
  • Inhbitors to io ibii Msteoe deacet lssse (HDAC) was by Martin. Ciottmaschine of Germany where be published ""Val ic acid defines a nov l class of HDAC inhibitors" in EMBQJour l 2$, pp 6969-697S, 2001.
  • R. md ii ® the same or diifeeat sh rlch3 ⁇ 4l3 ⁇ 4sd ssrboB based Hgao keludfeg without limitation, CHj. COjCH? or ; nd l&feCIb or Calls aed 3 ⁇ 4 Is O-E or hydogen; and where he chemical stmc&u- ⁇ hw the "S" someric co ilgiaamkm at t e C-l ' eblraf cafes go n
  • the preiOTed mem ers o dre d- erandrine family isdode the follo ing r resenative examples, w efe are »ot iBt mfed to be exhausive; dAeiraaddrie, isoietiaaddae, he.m3mle.:dee., beibarmae, .
  • the reloa t3 ⁇ 4r R md S coirhguratkm can be found m oms ⁇ arsd Boyd, Orgmk- Ckemkiry ⁇ m Edkio3 ⁇ 4 copyright 1913 by Al!ya aa.d-Bacot3 ⁇ 4 y -at p, 13 -14L
  • flfHS] il is bef levod thai the optlmom dosa e procedure would bo to adminter the d-teira;idri o famly moliMfUg teslsiaace revorser in cod d ⁇ s of Jkan about SO to about lilb rog per o s re ererer per day, more preferably 250-700, mil roost preferably about 500, (pto aMy in two to four doses per day) over a period of boos, a bins 4 u- about 14 days,
  • the dosage level tor the d- tetrandrbae family member will vary from cose to case, based on the patient aad on tbe primary anthcaacer drug(s) io3 ⁇ 43 ⁇ 4i
  • the principle noa-anglogeak cancer treating drug/s) is (are) tbea adorabstered t usu l
  • the tree base form is not sol le in wafer, However, it has recenly been surpdsbmly found by a a wcste that the tree base damda om of d-3 ⁇ 4trandrine fmiiy membes are absorbed into the bleodsft3 ⁇ 4am sab soloklly as .rapidl m ldn3 ⁇ 4u ] doaa o f die di-aeid salt meade?t tsf the isnbby. Accordingly, we propose to a*; either the tree base or the di-aeid sal.t fi.be ddeteandrbte femly merrs ' ber w our rmaladoas.
  • the preferred !domiktio3 ⁇ 4s comprise a mem r of the d-tetrasdrine family eembiaed with a suitable pharmaeeniioal carder,
  • the pharmaeexbical carder can be a liquid or a solid cornposhbom
  • a liq id carder will preferably comprise watep possibly with addidona!
  • P822J A :2 - ' .mg solid or l d dosage ferrnuiahoa is most preferred.
  • Adxcraocortica M ioiane ⁇ .;>. '-DDD
  • a drenoeon : ⁇ .c- Prednisone severe Aeuie artd chronic lysspboeytic; noo- sterods other e uivalent pre- ! !odgkitds lym homa disease; breast paratlons avail ble
  • e ADCC atop3 ⁇ 4 sk: Loading dose of 4 apCkg Cardiomyopathy; USIOB- mhi itionof HER2 j faskm fbdowed by 2 related ioxkity
  • Valproic acid, acs as a tomor suppressor gene abrral flb which inhibits the proli!eratioo of im f ceils before Cboy are transcribed from NA. by hlhibiting histonc dcacotykses.
  • Any combio hoo of two of Ibo: s iooglogeoic drugs bsted ab ve would be effective to preveoi vascularization of the tumor cell A fisrd .
  • Thalidomide Is thought to redu e hone n uro tumors associated with multiple nweionsO-s .by i3 ⁇ 4ve3 ⁇ 4 «g cancer cobs fmm creating a network of blood vessel, io sup y tbe tnroou De aooihasori acts to ouoke the thalidomide treatment more effective n pre enting this vasoakri aion.
  • P:2i The com as&m of: valproic acid, two aai1 ⁇ 2t iogSMC dugs, md a Mo-beazyl sis awke MDR mp ioblbdor cmtfd be added to lar ! it?erei3 ⁇ 4 i»eehaaiisms sed bf die eam r celts proliferate.
  • This combio fea - would wmk by Pie s me . ect oisms s in gastric cancer.
  • a ⁇ 3 ⁇ 4sik 5 carries of the above listed aadaogiogeofc drags,, aets to inhibit the 1 ⁇ 2mai3 ⁇ 4>5 of od essels s pplying the iuiisor. If Avasiln bibds nly a prseebsge of the fbrojadoo of blood vessels, the addfdoo of ooiber a iaoglogeaie drug ifeat works possibly via a di3 ⁇ 43 ⁇ 4resat mechansm aaay furdor inhibit sogi eae$3 ⁇ 4..
  • valproic 3 ⁇ 4ckl .or other MDAC inhibitor end a bis--3 ⁇ 4ri:3 ⁇ 4d. isorpimidJoe MDR. pump m b r could also hroteaso the «fSea « ef o a»a « am r tw£ tmmi:msd may ima se the nornbe of sk&ts with coaipte elminaton of ten rs.
  • omp nhibitor e.g. tetraiidrl e. '
  • the details of dosing ith iotrBiidlrse are covered m our previous patent on bis-ahen3 ⁇ 4yl isoqtdoeitnes inhibiting rno!hpte drag resistant carseer in humiffis (eum3 ⁇ 4si dosbig 300-609 mgday of tetrandnne. to the Avasflrs s3 ⁇ 4md&rd ebemmber&py would Increase the efficiency or elkacy of ihe ehoniodiera y..
  • VKGF vascalar adaihsbbd growth fac r
  • ECGF epbbebat cell gro * factor
  • Vaproic 3 ⁇ 4dd or other lsone de3 ⁇ 4eets3 ⁇ 4se inh mjrs (listed above) as tumor suppressor gene xtlmidaots
  • T!ie use of one bis- benzl oqeko!ioe such as t iisodrme or isotetraftdr e to irihibb the multiple dug resistant (MDE) .
  • MDE multiple dug resistant
  • a ooniblaapon of ca cer type s ec! H drugs to combat specific eaaces- See HoHsod a d FreL ' wurr Medicine M edition, B.C, Becker Ese 2000, p SS6-53 ⁇ 43 ⁇ 4 ibr specific cancer teas ⁇ e t com inations ⁇ .
  • the reater the resistance to the drug becomes.
  • the cell that t eatens to ksCame restsia to the aetl-ea o- drug -actually become more aeHSdlve to the aittl-caaioor drag.
  • Aw of the above listed IIDAC inhibitors should be e fective in activating, tamor sup ressor ems.
  • Valprehc acid lias proven to be i ⁇ powet blDAC i -Mtor, so It may be the Hi) AC Inhibitor of choke, for many c ⁇ iRoer ireiproorsts..
  • Valproic acd or lis s b - osier derivatives are cog nly FDA ap r ed for epilepy aed bipolar disease asd have oodergotte extensive clinical trials domoBStratlng those IHIAC jd.d d r t xn sup ressor siminl to be effective, in ixmassk See appendix fx details of ie d!flore (val rokaeid derivatives r ints) aad salts with, the correct d e.se Assy of die available Mstoae deaoetylase InMbdors coaid be meksdod in this gr p including those slid to be developed.
  • the list Is Bterdy to indicate examples.
  • bheior kappa b that are not steroids ss listed above uld be used aioneor added: to steroids merrhoned above.
  • Arsii-nEafHntatory steroids also Inhibit noek&r j3 ⁇ 4etor b as mil m strotiskte die roduction of de inhibitory factor known as i-kappa h,. alpha or tela etc. Doses of these drags are listed 3 ⁇ 43 ⁇ 4 ⁇ The Phy ician's Desk Refir ce (PDR)-bbih. edition..
  • !3 ⁇ 4e -foregomg is offered primarily for ur oses of ilh &tlofi. It will be readily apparent to those- of ordinary skill-, hi the tat that the o ea ng eonddiossL materi , proeedmal ste s arsd other parameters of the mveappn escri ed herein may be ferther modified or sobsdimed Io varkms ways wihout depart g from i e spird and scope of the iave icst for exam le, the .invention has heeo described with human patients, hat veiem y use Is coni&mpIar&T Th s the preceding description of the ireveatioo shook! oof he viewed s h mid rrg bat merely exemplary.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne le traitement du cancer par l'administration simultanée d'au moins trois, de préférence quatre, et idéalement de la totalité des agents suivants : (1) inhibiteurs de l'angiogenèse, (2) agents stimulants les gènes suppresseurs de tumeurs, (3) inhibiteurs de la protéine MDR, (4) agents anti-inflammatoires, et (5) agents chimiothérapeutiques anti-angiogenèse.
PCT/US2014/024729 2013-03-15 2014-03-12 Traitement contre le cancer Ceased WO2014150996A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361798807P 2013-03-15 2013-03-15
US61/798,807 2013-03-15

Publications (1)

Publication Number Publication Date
WO2014150996A1 true WO2014150996A1 (fr) 2014-09-25

Family

ID=51580870

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/024729 Ceased WO2014150996A1 (fr) 2013-03-15 2014-03-12 Traitement contre le cancer

Country Status (1)

Country Link
WO (1) WO2014150996A1 (fr)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962927B1 (en) * 1989-09-28 2005-11-08 Cancer Biologics Of America, Inc. Method for potentiating primary drugs in treating multidrug resistant disease
US20050250725A1 (en) * 2000-06-16 2005-11-10 Price Peter M Regulation of the P21 gene and uses thereof
EP1140192B1 (fr) * 1998-12-23 2006-04-05 G.D. Searle LLC Techniques permettant d'utiliser l'inhibiteur de cyclooxygenase-2 celecoxib et capectabine comme therapie combinee pour traiter les maladies neoplasiques
US20060121125A1 (en) * 2002-12-09 2006-06-08 Heinz Schneider Formulation which can be administered gastrointestinally, containing green tea extract and an no donor
US20060293358A1 (en) * 2005-06-23 2006-12-28 Dinsmore Christopher J Tyrosine kinase inhibitors
US20070134312A1 (en) * 2005-09-12 2007-06-14 Hussein Mohamad A Liposomes for treatment of multiple myeloma
WO2009155659A1 (fr) * 2008-06-27 2009-12-30 The University Of Queensland Polythérapie
US20100260674A1 (en) * 2006-12-15 2010-10-14 Concert Pharmaceuticals, Inc. Quinazoline derivatives and methods of treatment
WO2012164326A1 (fr) * 2011-06-01 2012-12-06 Hyd Rákkutató És Gyógyszerfejlesztő Kft. Compositions pharmaceutiques combinées pour le traitement de tumeurs

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962927B1 (en) * 1989-09-28 2005-11-08 Cancer Biologics Of America, Inc. Method for potentiating primary drugs in treating multidrug resistant disease
EP1140192B1 (fr) * 1998-12-23 2006-04-05 G.D. Searle LLC Techniques permettant d'utiliser l'inhibiteur de cyclooxygenase-2 celecoxib et capectabine comme therapie combinee pour traiter les maladies neoplasiques
US20050250725A1 (en) * 2000-06-16 2005-11-10 Price Peter M Regulation of the P21 gene and uses thereof
US20060121125A1 (en) * 2002-12-09 2006-06-08 Heinz Schneider Formulation which can be administered gastrointestinally, containing green tea extract and an no donor
US20060293358A1 (en) * 2005-06-23 2006-12-28 Dinsmore Christopher J Tyrosine kinase inhibitors
US20070134312A1 (en) * 2005-09-12 2007-06-14 Hussein Mohamad A Liposomes for treatment of multiple myeloma
US20100260674A1 (en) * 2006-12-15 2010-10-14 Concert Pharmaceuticals, Inc. Quinazoline derivatives and methods of treatment
WO2009155659A1 (fr) * 2008-06-27 2009-12-30 The University Of Queensland Polythérapie
WO2012164326A1 (fr) * 2011-06-01 2012-12-06 Hyd Rákkutató És Gyógyszerfejlesztő Kft. Compositions pharmaceutiques combinées pour le traitement de tumeurs

Similar Documents

Publication Publication Date Title
Gagliostro et al. Dihydroceramide delays cell cycle G1/S transition via activation of ER stress and induction of autophagy
Xia et al. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide)
Tolcher et al. A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors
Hensley et al. Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial
Singla et al. Induction with NCB-02 (curcumin) enema for mild-to-moderate distal ulcerative colitis—A randomized, placebo-controlled, pilot study
Park et al. A prospective, randomized, double-blind, multicenter comparative study on the safety and efficacy of Celecoxib and GCSB-5, dried extracts of six herbs, for the treatment of osteoarthritis of knee joint
KR20070045187A (ko) 항암제의 효과 증강제
Bauman et al. A phase I protocol of hydralazine and valproic acid in advanced, previously treated solid cancers
Gitlitz et al. A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial
Zhang et al. Oridonin effectively reverses the drug resistance of cisplatin involving induction of cell apoptosis and inhibition of MMP expression in human acute myeloid leukemia cells
Lin et al. Research progress of traditional Chinese medicine as sensitizer in reversing chemoresistance of colorectal cancer
Narayan Bhilwade et al. The adjuvant effect of squalene, an active ingredient of functional foods, on doxorubicin-treated allograft mice
Zapata-Morales et al. In vitro and in vivo synergistic interactions of the flavonoid rutin with paracetamol and with non-steroidal anti-inflammatory drugs
Choy et al. SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine‐Containing Therapy
Zhang et al. Frontline combination of 3 rd generation TKI olverembatinib and blinatumomab for Ph+/Ph-like ALL patients
Scanzello et al. The post-NSAID era: what to use now for the pharmacologic treatment of pain and inflammation in osteoarthritis
WO2016014390A1 (fr) Compositions et méthodes pour polythérapie à base d'inhibiteurs de mek dans le traitement du cancer
Ifora et al. Enhancing Chemotherapeutic Efficacy: Synergistic Cytotoxic Effect of Garcinia cowa Bark Extract and Doxorubicin in T47D Breast Cancer Cells.
Kirichenko et al. Radiation enhancement by 9-aminocamptothecin: the effect of fractionation and timing of administration
US20140275214A1 (en) Custirsen treatment with reduced toxicity
WO2014150996A1 (fr) Traitement contre le cancer
Sun et al. A phase 1 first-in-human monotherapy study of F182112, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma
Corry et al. Prospective study of cetuximab, carboplatin, and radiation therapy for patients with locally advanced head and neck squamous cell cancer unfit for cisplatin
Long III et al. Phase II trial of dacarbazine, mitomycin, doxorubicin, and cisplatin with sargramostim in uterine leiomyosarcoma: a Gynecologic Oncology Group study
El Bairi et al. Starvation tactics using natural compounds for advanced cancers: pharmacodynamics, clinical efficacy, and predictive biomarkers

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14768519

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14768519

Country of ref document: EP

Kind code of ref document: A1